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TAFIa Instability and its Role in Breast Cancer Metastasis 
Importance: Thrombin activatable fibrinolysis inhibitor (TAFI) is a plasma zymogen that can be 
activated to its active form TAFIa by thrombin in complex with thrombomodulin1. TAFIa has 
basic carboxypeptidase activity and is able to cleave carboxyl terminal lysine and arginine 
residues on various protein and peptide substrates, including cell-surface receptors for 
plasminogen1,2. Research in our laboratory has revealed that TAFIa plays a key role in reducing 
tumour invasion and migration in breast cancer 6. These studies aim to provide insight into 
potential strategies to therapeutically activate TAFI in order to prevent tumour cell invasion and 
migration in breast cancer. 
Existing State of Knowledge: TAFIa plays an important role in inhibiting pericellular 
plasminogen activation at the cell surface by cleaving carboxyl terminal lysine residues on 
plasminogen receptors, thus preventing the formation of plasmin8. Plasmin, along with matrix 
metalloproteases, degrades the extracellular matrix (ECM) to facilitate tumour cell invasion and 
metastasis as well as angiogenesis in breast cancer and to liberate ECM-associated growth 
factors6,8. Interestingly, TAFIa is intrinsically unstable with a half-life of approximately eight to 
fifteen minutes at body temperature7; more stable variants of TAFIa are correspondingly more 
effective in inhibiting fibrinolysis. It is unknown whether TAFIa instability similarly regulates its 
antimetastatic potential in breast cancer. In order to address this, recombinant variants of TAFI 
which differ in their intrinsic stability will be studied. 
Research Question: We hypothesize that TAFIa variants with an increased half-life will more 
effectively inhibit plasminogen activation and metastatic behaviour of breast cancer cells. 
Methodology: Recombinant variants of TAFI which differ in their intrinsic stability: Thr325 
(half-life of 8 minutes), Ile325 (15 minutes)3, R302Q (1.5 minutes)3 and a stable form of TAFIa 
consisting of five point mutations (1140 minutes)3-5 were constructed using site-directed 
mutagenesis. The Thr/Ile325 variants represent a common polymorphism observed in the human 
population3. Using triple negative MDA-MB 231 and SUM149 human breast cancer cell lines – 
which are characterized as highly invasive and metastatic – cell invasion, cell migration, 
extracellular proteolysis and cell proliferation assays will be performed utilizing the purified 
recombinant variants of TAFI differing in intrinsic stability. 
Findings: Preliminary experiments suggest that treatment with the activated stable form of TAFI 
decreases metastasis in breast cancer. This is the first direct evidence for an antimetastatic role, 
as our previous experiments used a potent inhibitor of TAFIa to show that inhibition of this 
enzyme stimulated metastasis. Further experimentation using activated Thr325, Ile325, and 
R302Q variants will be conducted. 
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